Tibet Rhodiola Pharmaceutical Holding Co (600211) - Net Assets
Based on the latest financial reports, Tibet Rhodiola Pharmaceutical Holding Co (600211) has net assets worth CN¥3.94 Billion CNY (≈ $576.66 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥5.82 Billion ≈ $851.11 Million USD) and total liabilities (CN¥1.88 Billion ≈ $274.45 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 600211 asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥3.94 Billion |
| % of Total Assets | 67.75% |
| Annual Growth Rate | 21.26% |
| 5-Year Change | 52.69% |
| 10-Year Change | 713.36% |
| Growth Volatility | 91.52 |
Tibet Rhodiola Pharmaceutical Holding Co - Net Assets Trend (1996–2024)
This chart illustrates how Tibet Rhodiola Pharmaceutical Holding Co's net assets have evolved over time, based on quarterly financial data. Also explore Tibet Rhodiola Pharmaceutical Holding Co asset portfolio for the complete picture of this company's asset base.
Annual Net Assets for Tibet Rhodiola Pharmaceutical Holding Co (1996–2024)
The table below shows the annual net assets of Tibet Rhodiola Pharmaceutical Holding Co from 1996 to 2024. For live valuation and market cap data, see how much is Tibet Rhodiola Pharmaceutical Holding Co worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥3.95 Billion ≈ $578.32 Million |
+17.15% |
| 2023-12-31 | CN¥3.37 Billion ≈ $493.67 Million |
+11.31% |
| 2022-12-31 | CN¥3.03 Billion ≈ $443.50 Million |
+14.58% |
| 2021-12-31 | CN¥2.65 Billion ≈ $387.05 Million |
+2.19% |
| 2020-12-31 | CN¥2.59 Billion ≈ $378.76 Million |
+5.79% |
| 2019-12-31 | CN¥2.45 Billion ≈ $358.04 Million |
+8.40% |
| 2018-12-31 | CN¥2.26 Billion ≈ $330.29 Million |
+10.35% |
| 2017-12-31 | CN¥2.05 Billion ≈ $299.31 Million |
+210.76% |
| 2016-12-31 | CN¥658.19 Million ≈ $96.31 Million |
+35.46% |
| 2015-12-31 | CN¥485.90 Million ≈ $71.10 Million |
+17.32% |
| 2014-12-31 | CN¥414.18 Million ≈ $60.61 Million |
+3.75% |
| 2013-12-31 | CN¥399.20 Million ≈ $58.42 Million |
+3.57% |
| 2012-12-31 | CN¥385.44 Million ≈ $56.40 Million |
+8.59% |
| 2011-12-31 | CN¥354.94 Million ≈ $51.94 Million |
+9.48% |
| 2010-12-31 | CN¥324.19 Million ≈ $47.44 Million |
+8.06% |
| 2009-12-31 | CN¥300.00 Million ≈ $43.90 Million |
+7.47% |
| 2008-12-31 | CN¥279.15 Million ≈ $40.85 Million |
+1.78% |
| 2007-12-31 | CN¥274.28 Million ≈ $40.14 Million |
-30.80% |
| 2006-12-31 | CN¥396.34 Million ≈ $58.00 Million |
+0.79% |
| 2005-12-31 | CN¥393.25 Million ≈ $57.54 Million |
-9.70% |
| 2004-12-31 | CN¥435.51 Million ≈ $63.73 Million |
+2.59% |
| 2003-12-31 | CN¥424.53 Million ≈ $62.12 Million |
+1.36% |
| 2002-12-31 | CN¥418.85 Million ≈ $61.29 Million |
+3.04% |
| 2001-12-31 | CN¥406.50 Million ≈ $59.48 Million |
+1.03% |
| 2000-12-31 | CN¥402.35 Million ≈ $58.88 Million |
+3.24% |
| 1999-12-31 | CN¥389.71 Million ≈ $57.03 Million |
+285.93% |
| 1998-12-31 | CN¥100.98 Million ≈ $14.78 Million |
+18.33% |
| 1997-12-31 | CN¥85.34 Million ≈ $12.49 Million |
+376.84% |
| 1996-12-31 | CN¥17.90 Million ≈ $2.62 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Tibet Rhodiola Pharmaceutical Holding Co's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 216651500000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥2.17 Billion | 55.30% |
| Common Stock | CN¥322.32 Million | 8.23% |
| Other Comprehensive Income | CN¥247.86 Million | 6.33% |
| Other Components | CN¥1.18 Billion | 30.15% |
| Total Equity | CN¥3.92 Billion | 100.00% |
Tibet Rhodiola Pharmaceutical Holding Co Competitors by Market Cap
The table below lists competitors of Tibet Rhodiola Pharmaceutical Holding Co ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Aecon Group Inc.
TO:ARE
|
$1.96 Billion |
|
Punjab & Sind Bank
NSE:PSB
|
$1.96 Billion |
|
NCC AB (publ)
ST:NCC-B
|
$1.96 Billion |
|
Suzhou Nanomicro Technology Co Ltd
SHG:688690
|
$1.96 Billion |
|
Syngene International Limited
NSE:SYNGENE
|
$1.96 Billion |
|
Stolt-Nielsen Limited
LSE:0OHK
|
$1.95 Billion |
|
ChipMOS Technologies
TW:8150
|
$1.95 Billion |
|
Coty Inc
NYSE:COTY
|
$1.95 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Tibet Rhodiola Pharmaceutical Holding Co's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 3,344,589,000 to 3,917,817,000, a change of 573,228,000 (17.1%).
- Net income of 1,051,288,313 contributed positively to equity growth.
- Dividend payments of 504,053,000 reduced retained earnings.
- Other comprehensive income increased equity by 53,542,672.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥1.05 Billion | +26.83% |
| Dividends Paid | CN¥504.05 Million | -12.87% |
| Other Comprehensive Income | CN¥53.54 Million | +1.37% |
| Other Changes | CN¥-27.55 Million | -0.7% |
| Total Change | CN¥- | 17.14% |
Book Value vs Market Value Analysis
This analysis compares Tibet Rhodiola Pharmaceutical Holding Co's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.42x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 637.75x to 3.42x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1996-12-31 | CN¥0.07 | CN¥41.50 | x |
| 1997-12-31 | CN¥0.31 | CN¥41.50 | x |
| 1998-12-31 | CN¥0.35 | CN¥41.50 | x |
| 1999-12-31 | CN¥1.42 | CN¥41.50 | x |
| 2000-12-31 | CN¥1.46 | CN¥41.50 | x |
| 2001-12-31 | CN¥1.47 | CN¥41.50 | x |
| 2002-12-31 | CN¥1.51 | CN¥41.50 | x |
| 2003-12-31 | CN¥1.53 | CN¥41.50 | x |
| 2004-12-31 | CN¥1.55 | CN¥41.50 | x |
| 2005-12-31 | CN¥1.40 | CN¥41.50 | x |
| 2006-12-31 | CN¥1.85 | CN¥41.50 | x |
| 2007-12-31 | CN¥1.26 | CN¥41.50 | x |
| 2008-12-31 | CN¥1.38 | CN¥41.50 | x |
| 2009-12-31 | CN¥1.56 | CN¥41.50 | x |
| 2010-12-31 | CN¥1.19 | CN¥41.50 | x |
| 2011-12-31 | CN¥1.66 | CN¥41.50 | x |
| 2012-12-31 | CN¥1.83 | CN¥41.50 | x |
| 2013-12-31 | CN¥1.47 | CN¥41.50 | x |
| 2014-12-31 | CN¥1.93 | CN¥41.50 | x |
| 2015-12-31 | CN¥2.40 | CN¥41.50 | x |
| 2016-12-31 | CN¥3.24 | CN¥41.50 | x |
| 2017-12-31 | CN¥8.67 | CN¥41.50 | x |
| 2018-12-31 | CN¥8.95 | CN¥41.50 | x |
| 2019-12-31 | CN¥9.75 | CN¥41.50 | x |
| 2020-12-31 | CN¥10.39 | CN¥41.50 | x |
| 2021-12-31 | CN¥10.61 | CN¥41.50 | x |
| 2022-12-31 | CN¥12.15 | CN¥41.50 | x |
| 2023-12-31 | CN¥10.36 | CN¥41.50 | x |
| 2024-12-31 | CN¥12.15 | CN¥41.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Tibet Rhodiola Pharmaceutical Holding Co utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 26.83%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 37.46%
- • Asset Turnover: 0.59x
- • Equity Multiplier: 1.21x
- Recent ROE (26.83%) is above the historical average (9.31%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1996 | 31.27% | 25.84% | 0.46x | 2.64x | CN¥3.81 Million |
| 1997 | 23.29% | 41.16% | 0.40x | 1.40x | CN¥11.34 Million |
| 1998 | 33.04% | 40.91% | 0.45x | 1.79x | CN¥22.27 Million |
| 1999 | 8.49% | 39.87% | 0.19x | 1.12x | CN¥-5.90 Million |
| 2000 | 7.73% | 37.28% | 0.16x | 1.32x | CN¥-9.12 Million |
| 2001 | 4.53% | 24.51% | 0.12x | 1.51x | CN¥-22.12 Million |
| 2002 | 2.46% | 13.69% | 0.10x | 1.77x | CN¥-31.24 Million |
| 2003 | 1.37% | 7.69% | 0.10x | 1.80x | CN¥-36.24 Million |
| 2004 | 1.43% | 3.33% | 0.24x | 1.82x | CN¥-36.54 Million |
| 2005 | -10.74% | -5.93% | 0.85x | 2.13x | CN¥-79.81 Million |
| 2006 | 1.05% | 0.47% | 0.99x | 2.23x | CN¥-34.71 Million |
| 2007 | -46.53% | -15.22% | 0.99x | 3.09x | CN¥-152.19 Million |
| 2008 | 2.35% | 0.65% | 1.19x | 3.01x | CN¥-21.08 Million |
| 2009 | 6.85% | 1.82% | 1.49x | 2.52x | CN¥-9.27 Million |
| 2010 | 7.37% | 2.12% | 1.51x | 2.30x | CN¥-8.39 Million |
| 2011 | 6.03% | 1.90% | 1.37x | 2.32x | CN¥-13.48 Million |
| 2012 | 8.21% | 2.50% | 1.45x | 2.27x | CN¥-6.63 Million |
| 2013 | 6.99% | 1.94% | 1.23x | 2.93x | CN¥-11.71 Million |
| 2014 | 5.19% | 1.26% | 1.59x | 2.59x | CN¥-19.46 Million |
| 2015 | 18.72% | 6.63% | 1.96x | 1.44x | CN¥42.69 Million |
| 2016 | 30.01% | 24.89% | 0.35x | 3.47x | CN¥132.23 Million |
| 2017 | 11.24% | 25.08% | 0.39x | 1.14x | CN¥25.33 Million |
| 2018 | 9.57% | 20.98% | 0.41x | 1.12x | CN¥-9.64 Million |
| 2019 | 12.82% | 24.87% | 0.45x | 1.14x | CN¥68.62 Million |
| 2020 | 16.23% | 30.45% | 0.47x | 1.14x | CN¥160.49 Million |
| 2021 | 7.94% | 9.77% | 0.56x | 1.45x | CN¥-54.10 Million |
| 2022 | 12.28% | 14.48% | 0.62x | 1.36x | CN¥68.67 Million |
| 2023 | 23.95% | 25.55% | 0.68x | 1.37x | CN¥466.46 Million |
| 2024 | 26.83% | 37.46% | 0.59x | 1.21x | CN¥659.51 Million |
Industry Comparison
This section compares Tibet Rhodiola Pharmaceutical Holding Co's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $4,691,234,838
- Average return on equity (ROE) among peers: 6.16%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Tibet Rhodiola Pharmaceutical Holding Co (600211) | CN¥3.94 Billion | 31.27% | 0.48x | $1.96 Billion |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $903.62 Million | 4.28% | 2.45x | $1.16 Billion |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $1.22 Billion | 5.35% | 1.27x | $441.99 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $9.87 Billion | 20.71% | 0.25x | $5.01 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $1.07 Billion | 3.83% | 0.46x | $2.80 Billion |
| Wedge Industrial Co Ltd (000534) | $1.15 Billion | 11.42% | 1.59x | $3.04 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $9.03 Billion | 25.71% | 0.43x | $13.75 Billion |
| Hainan Haiyao Co Ltd (000566) | $275.57 Million | 17.28% | 1.12x | $947.33 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $231.22 Million | -38.13% | 1.23x | $389.67 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $4.29 Billion | 2.31% | 2.07x | $1.03 Billion |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $18.87 Billion | 8.83% | 0.08x | $3.32 Billion |
About Tibet Rhodiola Pharmaceutical Holding Co
Tibet Rhodiola Pharmaceutical Holding Co. manufactures pharmaceuticals in China and internationally. The company offers biological products, Tibetan medicine, Chinese medicine, and chemical medicine products. It also provides capsules, biological preparations, granules, and film-coating agents for cardiovascular, cerebrovascular, hepatobiliary, sprains and contusions, rheumatism, rheumatoid arthr… Read more